Compare Gilead Sciences, Inc. (GILD) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? Gilead Sciences, Inc. trades at $132.91 (market cap $163.51B), while Royal Caribbean Cruises Ltd trades at $292.23 (market cap $78.36B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Royal Caribbean Cruises Ltd's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | RCL | |
|---|---|---|
Market Cap | $163.51B | $78.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $365.84 |
52-Week Low | $108.22 | $246.71 |
Enterprise Value | $178.05B | $99.64B |
Dividend Yield | 2.49% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Royal Caribbean (RCL) trades at $283.09, down 1.91% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. Fundamentally, the company demonstrates strong profitability with 24.36% net margins and 50.41% ROE, supported by consistent revenue growth from $8.8B in 2022 to $17.9B in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed.
The stock offers 16% upside to the consensus price target of $328, with analysts maintaining a buy-heavy stance (48% buy ratings). Key risks include Europe weakness offset by Caribbean strength, high debt levels, and competitive pressures. Cash flow trends show improving operational performance with $6.5B operating cash flow in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
